{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T05:24:52.910406+00:00","company":{"ticker":"OKUR","cik":1637715,"company_name":"OnKure Therapeutics, Inc."},"pagination":{"limit":100,"returned":17,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"76868286ada40c91eb7230c6b3249af0aceffaaa","cik":1637715,"ticker":"OKUR","company_name":"OnKure Therapeutics, Inc.","filed_at":"2026-05-05T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the first quarter ended March 31, 2026","report_date":"2026-05-05","result_type":"reported_results","revenue_text":null},"claim":"OnKure Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2026.","evidence_excerpt":"OnKure Therapeutics, Inc. issued a press release reporting financial results for the quarter ended March 31, 2026.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-206396","anchor_url":"https://secwatch.observer/filing/0001193125-26-206396#claim-76868286ada40c91eb7230c6b3249af0aceffaaa","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312526206396/0001193125-26-206396-index.htm"},{"fact_type":"material_agreement","fact_key":"be41db4e9c04a1aea5f6b193fe57a1f33cd6e3f4","cik":1637715,"ticker":"OKUR","company_name":"OnKure Therapeutics, Inc.","filed_at":"2026-03-30T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Registration Rights Agreement","agreement_type":"equity_purchase","counterparty":"the Company and the Investors","effective_date":"2026-03-27","item_codes_triggered":["1.01"],"value_text":null},"claim":"OnKure Therapeutics, Inc. entered into Registration Rights Agreement with the Company and the Investors (effective 2026-03-27).","evidence_excerpt":"the Company and the Investors also entered into a Registration Rights Agreement, dated March 27, 2026 (the “Registration Rights Agreement”), providing for the registration for resale of the Shares and the Warrant Shares, pursuant to a registration statement (the “Registration Statement”) to be filed with the SEC within 30 days after the Closing Date.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-130283","anchor_url":"https://secwatch.observer/filing/0001193125-26-130283#claim-be41db4e9c04a1aea5f6b193fe57a1f33cd6e3f4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312526130283/0001193125-26-130283-index.htm"},{"fact_type":"material_agreement","fact_key":"930c2ec954fdcf3cb09e72439f9326094ff1d0a0","cik":1637715,"ticker":"OKUR","company_name":"OnKure Therapeutics, Inc.","filed_at":"2026-03-30T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase Agreement","agreement_type":"equity_purchase","counterparty":"certain institutional accredited investors","effective_date":"2026-03-27","item_codes_triggered":["1.01"],"value_text":"approximately $150.0 million"},"claim":"OnKure Therapeutics, Inc. entered into Purchase Agreement with certain institutional accredited investors valued at approximately $150.0 million (effective 2026-03-27).","evidence_excerpt":"On March 27, 2026, OnKure Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement (i) 26,713,636 shares (the “Shares”) of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), at a purchase price of $4.15 per Share, and (ii) pre-funded warrants (the “Pre-Funded Warrants” and together with the Shares, the “Securities”) to purchase 9,430,959 shares of Common Stock (the “Warrant Shares”), at a purchase price of $4.1499 per underlying Warrant Share (the “Private Placement”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-130283","anchor_url":"https://secwatch.observer/filing/0001193125-26-130283#claim-930c2ec954fdcf3cb09e72439f9326094ff1d0a0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312526130283/0001193125-26-130283-index.htm"},{"fact_type":"executive_change","fact_key":"63ff7dd157","cik":1637715,"ticker":"OKUR","company_name":"OnKure Therapeutics, Inc.","filed_at":"2024-10-08T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-10-04","interim":false,"role":"Chair of the Board","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Andrew Phillips was appointed as Chair of the Board at OnKure Therapeutics, Inc..","evidence_excerpt":"Also on October 4, 2024, Andrew Phillips, Ph.D. was appointed as the Chair of the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-234487","anchor_url":"https://secwatch.observer/filing/0001193125-24-234487#claim-63ff7dd157","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/0001193125-24-234487-index.htm"},{"fact_type":"executive_change","fact_key":"f8c7f29f15","cik":1637715,"ticker":"OKUR","company_name":"OnKure Therapeutics, Inc.","filed_at":"2024-10-08T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-10-04","interim":false,"role":"Class III Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Michael Grey was appointed as Class III Director at OnKure Therapeutics, Inc..","evidence_excerpt":"Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-234487","anchor_url":"https://secwatch.observer/filing/0001193125-24-234487#claim-f8c7f29f15","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/0001193125-24-234487-index.htm"},{"fact_type":"executive_change","fact_key":"a80378c5e3","cik":1637715,"ticker":"OKUR","company_name":"OnKure Therapeutics, Inc.","filed_at":"2024-10-08T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-10-04","interim":false,"role":"Class III Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Andrew Phillips was appointed as Class III Director at OnKure Therapeutics, Inc..","evidence_excerpt":"Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-234487","anchor_url":"https://secwatch.observer/filing/0001193125-24-234487#claim-a80378c5e3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/0001193125-24-234487-index.htm"},{"fact_type":"executive_change","fact_key":"a659d4c982","cik":1637715,"ticker":"OKUR","company_name":"OnKure Therapeutics, Inc.","filed_at":"2024-10-08T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-10-04","interim":false,"role":"Class II Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Edward T. Mathers was appointed as Class II Director at OnKure Therapeutics, Inc..","evidence_excerpt":"Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-234487","anchor_url":"https://secwatch.observer/filing/0001193125-24-234487#claim-a659d4c982","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/0001193125-24-234487-index.htm"},{"fact_type":"executive_change","fact_key":"daec546b9b","cik":1637715,"ticker":"OKUR","company_name":"OnKure Therapeutics, Inc.","filed_at":"2024-10-08T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-10-04","interim":false,"role":"Class II Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Valerie M. Jansen was appointed as Class II Director at OnKure Therapeutics, Inc..","evidence_excerpt":"Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-234487","anchor_url":"https://secwatch.observer/filing/0001193125-24-234487#claim-daec546b9b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/0001193125-24-234487-index.htm"},{"fact_type":"executive_change","fact_key":"c5d8145dca","cik":1637715,"ticker":"OKUR","company_name":"OnKure Therapeutics, Inc.","filed_at":"2024-10-08T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-10-04","interim":false,"role":"Class II Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"R. Michael Carruthers was appointed as Class II Director at OnKure Therapeutics, Inc..","evidence_excerpt":"Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-234487","anchor_url":"https://secwatch.observer/filing/0001193125-24-234487#claim-c5d8145dca","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/0001193125-24-234487-index.htm"},{"fact_type":"executive_change","fact_key":"01b06402d4","cik":1637715,"ticker":"OKUR","company_name":"OnKure Therapeutics, Inc.","filed_at":"2024-10-08T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-10-04","interim":false,"role":"Class I Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Isaac Manke was appointed as Class I Director at OnKure Therapeutics, Inc..","evidence_excerpt":"Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-234487","anchor_url":"https://secwatch.observer/filing/0001193125-24-234487#claim-01b06402d4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/0001193125-24-234487-index.htm"},{"fact_type":"executive_change","fact_key":"a76135e34c","cik":1637715,"ticker":"OKUR","company_name":"OnKure Therapeutics, Inc.","filed_at":"2024-10-08T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-10-04","interim":false,"role":"Class I Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Nicholas Saccomano was appointed as Class I Director at OnKure Therapeutics, Inc..","evidence_excerpt":"Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-234487","anchor_url":"https://secwatch.observer/filing/0001193125-24-234487#claim-a76135e34c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/0001193125-24-234487-index.htm"},{"fact_type":"executive_change","fact_key":"e640771d75","cik":1637715,"ticker":"OKUR","company_name":"OnKure Therapeutics, Inc.","filed_at":"2024-09-13T23:59:59+00:00","payload":{"action":"terminated","action_category":"departure","departure_tone":"termination","effective_date":"2024-09-13","interim":false,"role":"Chief Development Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Ashley F. Hall was terminated as Chief Development Officer at OnKure Therapeutics, Inc..","evidence_excerpt":"the Company terminated the employment of Ashley F. Hall, J.D., the Company’s Chief Development Officer, effective as of September 13, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-218879","anchor_url":"https://secwatch.observer/filing/0001193125-24-218879#claim-e640771d75","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312524218879/0001193125-24-218879-index.htm"},{"fact_type":"material_agreement","fact_key":"1746ee1b50689d1d968bbff32e986f17c69ed14a","cik":1637715,"ticker":"OKUR","company_name":"OnKure Therapeutics, Inc.","filed_at":"2024-05-13T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Merger Agreement","agreement_type":"merger","counterparty":"Reneo Pharmaceuticals, Inc.","effective_date":"2024-05-10","item_codes_triggered":["1.01"],"value_text":null},"claim":"OnKure Therapeutics, Inc. entered into Merger Agreement with Reneo Pharmaceuticals, Inc. (effective 2024-05-10).","evidence_excerpt":"On May 10, 2024, Reneo Pharmaceuticals, Inc., a Delaware corporation (“ Reneo ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among Reneo, Radiate Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Reneo (“ Merger Sub I ”), Radiate Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly owned subsidiary of Reneo (“ Merger Sub II ”), and OnKure, Inc., a Delaware corporation (“ OnKure ”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-24-136785","anchor_url":"https://secwatch.observer/filing/0001193125-24-136785#claim-1746ee1b50689d1d968bbff32e986f17c69ed14a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312524136785/0001193125-24-136785-index.htm"},{"fact_type":"executive_change","fact_key":"0c41110b87","cik":1637715,"ticker":"OKUR","company_name":"OnKure Therapeutics, Inc.","filed_at":"2024-05-13T23:59:59+00:00","payload":{"action":"resign","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":null,"role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Ashley F. Hall departed as other_named_officer at OnKure Therapeutics, Inc..","evidence_excerpt":"each of Mr. Flesher, Mr.Dorenbaum, and Ms. Hall are expected to resign as executive officers of Reneo.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-136785","anchor_url":"https://secwatch.observer/filing/0001193125-24-136785#claim-0c41110b87","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312524136785/0001193125-24-136785-index.htm"},{"fact_type":"executive_change","fact_key":"7478c412a4","cik":1637715,"ticker":"OKUR","company_name":"OnKure Therapeutics, Inc.","filed_at":"2024-05-13T23:59:59+00:00","payload":{"action":"resign","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":null,"role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Alejandro Dorenbaum departed as other_named_officer at OnKure Therapeutics, Inc..","evidence_excerpt":"each of Mr. Flesher, Mr.Dorenbaum, and Ms. Hall are expected to resign as executive officers of Reneo.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-136785","anchor_url":"https://secwatch.observer/filing/0001193125-24-136785#claim-7478c412a4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312524136785/0001193125-24-136785-index.htm"},{"fact_type":"executive_change","fact_key":"c558459de6","cik":1637715,"ticker":"OKUR","company_name":"OnKure Therapeutics, Inc.","filed_at":"2024-05-13T23:59:59+00:00","payload":{"action":"resign","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":null,"role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Gregory J. Flesher departed as other_named_officer at OnKure Therapeutics, Inc..","evidence_excerpt":"each of Mr. Flesher, Mr.Dorenbaum, and Ms. Hall are expected to resign as executive officers of Reneo.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-136785","anchor_url":"https://secwatch.observer/filing/0001193125-24-136785#claim-c558459de6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312524136785/0001193125-24-136785-index.htm"},{"fact_type":"earnings_release","fact_key":"aa9fbaf5bed2bf9df4317acc97cf2333725f806e","cik":1637715,"ticker":"OKUR","company_name":"OnKure Therapeutics, Inc.","filed_at":"2024-05-07T23:59:59+00:00","payload":{"eps_text":"$0.25 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss of $8.4 million, or $0.25 per share","period_text":"first quarter ended March 31, 2024","report_date":"2024-05-07","result_type":"reported_results","revenue_text":null},"claim":"OnKure Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income net loss of $8.4 million, or $0.25 per share, EPS $0.25 per share.","evidence_excerpt":"We reported a net loss of $8.4 million, or $0.25 per share, during the first quarter of 2024, compared to a net loss of $15.1 million, or $0.60 per share, for the same period in 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-054442","anchor_url":"https://secwatch.observer/filing/0000950170-24-054442#claim-aa9fbaf5bed2bf9df4317acc97cf2333725f806e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1637715/000095017024054442/0000950170-24-054442-index.htm"}]}